Lutathera®, a radioligand therapy by Novartis, showed significant progression-free survival rates in initial stage advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).

SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.

Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.

Jazz Pharmaceuticals plc has proclaimed that the EC has approved the commercialization of Enrylaze®(JZP458; a derivative of Erwinia asparaginase or crisantaspase).

Leucid Bio announced today its UK MHRA-approved CTA to commence Phase 1/2 AERIAL clinical trials of its drug, LEU011, for treating adult patients with relapsed or resistant solid tumours.

Bristol Myers Squibb states that a pre/postoperative regimen of Opdivo (nivolumab) and chemotherapy significantly improves survival in operable non-small cell lung cancer patients.

Inmagene has established Celexor Bio, which is premised on its anti-ILT7 mAb that demonstrates improved pDC reduction capabilities.

The Phase 3 TROPION-Breast01 trial showed that Datopotamab Deruxtecan significantly improved progression-free survival for patients with HR positive, HER2 low or negative breast cancer.

Antengene Corp Ltd obtained approval from University of Texas MD Anderson Cancer Center's Institutional Review Board for a Phase I trial of its prime anti-CD24 antibody, ATG-031, focusing on advanced hematology and oncology solutions.

Alvotech declared today that the U.S. FDA has agreed to Alvotech's revised BLA for AVT02.

Vir Biotechnology, Inc. reports first participant dosed in Phase 1 trial evaluating safety, reactogenicity, and immunogenicity of VIR-1388.